Trial Profile
A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2020
Price :
$35
*
At a glance
- Drugs Baltaleucel-T (Primary)
- Indications Diffuse large B cell lymphoma; Hodgkin's disease; Post-transplant lymphoproliferative disorder
- Focus Therapeutic Use
- Acronyms CIVIC
- Sponsors Kuur Therapeutics
- 10 Mar 2020 According to an Kuur Therapeutics media release, Cell Medica has changed its name to Kuur Therapeutics.
- 10 Jan 2019 Status changed from recruiting to discontinued.
- 27 Dec 2016 Status changed from not yet recruiting to recruiting.